The TRINITI-1 trial evaluated the triplet regimen of ribociclib, everolimus, and exemestane in HR+/HER2− advanced breast cancer patients who had progressed on prior CDK4/6 inhibitor therapy. Here, CDK4 is linked to breast cancer.